References in periodicals archive ?
Food and Drug Administration ("FDA") to initiate the Long-term Efficacy in AMD from Rheopheresis in North America ("LEARN-1 and LEARN-2") protocols.
Gil's great clinical and scientific accomplishments, and his experience on the Boards of various public companies, professional associations and social institutions, will be a tremendous asset to OccuLogix as we work toward bringing to fruition the potential Rheopheresis represents in delivering hope for the first time to the millions of people suffering from Dry AMD.
Food and Drug Administration ("FDA") has completed a review of the Long-term Efficacy in AMD from Rheopheresis in North America ("LEARN") protocols submitted to it by OccuLogix on January 21, 2005, and has given OccuLogix permission to initiate the studies.
OccuLogix's RHEO System is being evaluated to determine whether it will improve micro-vascular circulation in the eye by filtering high molecular weight proteins and other macromolecules from the patient's plasma through a treatment process known as Rheopheresis.
RHEO CLINIC, a subsidiary of TLC Vision Corporation (Nasdaq:TLCV) (TSX:TLC), announced today Institutional Review Board ("IRB") approval and the official launch of patient enrollment in a new study called the Prospective Evaluation of Visual Functioning with Rheopheresis Treatment for Age-related Macular Degeneration in Canada ("PERC").
Clinical evidence has shown that certain high-risk AMD patients suffering from the dry form of the disease demonstrated visual improvement following rheopheresis.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, relating principally to Vascular Sciences' ability to complete clinical trials for Rheopheresis and file a Pre-Market Approval application (PMA) with the U.
Rheopheresis is a process that filters from the blood certain high molecular weight plasma proteins and lipoproteins which are believed to contribute to the development of AMD.
Product Overview II-16 Therapeutic Apheresis: An Introduction II-16 Overview of Therapeutic Apheresis II-16 Blood Components II-16 Apheresis and Therapeutic Apheresis: The Difference II-17 Therapeutic Apheresis Process II-17 Duration, Frequency, and Efficiency of Therapeutic Apheresis II-17 Segregation of Blood Components II-17 Centrifugation II-17 Filtration II-18 History II-18 Kinds of Therapeutic Apheresis Procedures II-18 Plasmapheresis II-19 Erythrocytapheresis II-19 Plateletpheresis II-19 Leukapheresis II-19 Stem Cell Apheresis II-19 Photopheresis II-19 Lipidpheresis II-20 Cytapheresis II-20 Immunoadsorption II-20 Rheopheresis II-20 Therapeutic Apheresis is Remedial for Various Diseases II-20
In December 2004, OccuLogix completed enrollment for participation in MIRA-1, or Multicenter Investigation of Rheopheresis for AMD, its pivotal (phase III) stage clinical trial using its RHEO(TM) System to treat Dry AMD.
In December 2004, OccuLogix completed enrollment for participation in MIRA-1, or Multicenter Investigation of Rheopheresis for AMD, its pivotal stage clinical trial using its RHEO(TM) System to treat the dry form of age-related macular degeneration ("Dry AMD").
today presented Rheopheresis(TM) ("RHEO(TM)") efficacy data from the Prospective Evaluation of Visual Functioning with Rheopheresis Treatment for Age-related Macular Degeneration in Canada ("PERC") protocol at the American Society of Retinal Specialists ("ASRS") Annual Meeting in Montreal, Quebec.
Medical browser ?
- rhegmatogenous retinal detachment
- Rheinberg microscope
- Rhese projection
- rhesus blood group
- rhesus disease
- Rhesus factor
- rhesus factor disease
- rhesus haemolytic anaemia
- rhesus monkey
- Rheum palmatum
- Rheum rhaponticum
- rheumatic aortitis
- rheumatic arteritis
- rheumatic carditis
- rheumatic chorea
Full browser ?
- rheomorphic intrusion
- rheopectic fluid
- Rheophile Animal
- rheophilous bog
- rheostat pedal
- rheostat pedal
- rheostat pedal
- Rheostatic brake
- rheostatic braking
- rheostatic control